Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

BACKGROUND: An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor genome, as determined from tumor tissue (tTMB) or blood (bTMB). While high tTMB is a biomar...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jie, Kalinava, Natallia, Doshi, Parul, Pavlick, Dean C, Albacker, Lee A, Ebot, Ericka M, Tukachinsky, Hanna, Pratt, James, Fusaro, Gina, Oxnard, Geoffrey R, Green, George, Fabrizio, David, Baden, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689409/
https://www.ncbi.nlm.nih.gov/pubmed/38035725
http://dx.doi.org/10.1136/jitc-2023-007339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689409/
https://www.ncbi.nlm.nih.gov/pubmed/38035725
http://dx.doi.org/10.1136/jitc-2023-007339

Ejemplares similares